ScreenerHero
CRLCharles River Laboratories International, Inc.
NYSE · US · Healthcare · Diagnostics & Research · criver.com
290.87USD+0.30%Mkt Cap: 13.84B $P/E: —

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Mode…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group AG
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8

Key Statistics

Company
Market Cap13.84B $
Enterprise Value16.80B $
Revenue (TTM)4.00B $
Gross Profit1.32B $
Net Income (TTM)-144.34M $
Revenue/Share81.86 USD
Last Price290.87 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18.3K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS1598641074
Valuation
P/E (Trailing)—
P/E (Forward)22.97
PEG0.12
EV/EBITDA19.79
EV/Revenue4.20
P/S3.51
P/B4.90
EPS (TTM)-4.84
EPS (Forward)12.69
52W Range
144.2698% of range294.55
52W High294.55 USD
52W Low144.26 USD
Profitability
Gross Margin32.96%
Oper. Margin15.11%
EBITDA Margin21.23%
Profit Margin-3.59%
ROE-4.56%
ROA-2.02%
Growth
Revenue Growth-2.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF737.65M $
CapEx (TTM)219.15M $
FCF Margin11.72%
FCF Yield3.39%
Net Debt2.84B $
Net Debt/EBITDA3.35
Balance Sheet
Debt/Equity0.81
Current Ratio1.35
Quick Ratio0.80
Book Value/Sh59.50 USD
Cash/Share4.022 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)281.00 USD
Upside (mean)-3.4%
Target Range145.00 USD – 318.00 USD
$145.00-3.4% to mean$318.00
# Analysts14
Ownership
Shares Out.47.74M
Float47.22M
Insiders0.47%
Institutions123.08%
Short Interest
Short Ratio4.0d
Short % Float8.28%
Short % Out.7.16%
Shares Short3.42M
Short (prev mo.)4.35M
Technical
SMA 50231.96 (+25.4%)
SMA 200193.44 (+50.4%)
Beta1.38
S&P 52W Chg18.16%
Avg Vol (30d)768.23K
Avg Vol (10d)939.69K
Technical Indicators
RSI (14)79.5
MACD18.0583
MACD Signal15.3131
MACD Hist.+2.7453
BB Upper304.72 USD
BB Middle254.06 USD
BB Lower203.41 USD
BB Width39.88%
ATR (14)10.12 USD
Vol Ratio (20d)1.12x